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Three main forms of skin cancer, depending on the 
type of epidermal cells affected, are basal cell carci-
noma, squamous cell carcinoma and cutaneous mela-
noma. Our research is focused on two of them, i.e. 
basal cell carcinoma (BCC) as the most common skin 
neoplasm, and melanoma as the most aggressive skin 
cancer. Although widespread and with increasing in-
cidence, both were not well understood at the level of 
molecular pathogenesis until recently. Progress over 
the past decade has identified an array of molecular 
alterations in these neoplasms that may provide op-
portunities for new molecular therapeutics. A number 
of genetic alterations have been characterized, some 
of them involving gain-of-function changes in on-
cogenes, whereas others involve loss-of-function of 
genes that act as suppressors of tumor formation. The 
spectrum of changes differs among these tumor types. 
Major events in BCC onset and development are 
various alterations in the Sonic Hedgehog/Patched/
Smoothened (SHH/PTCH/SMO) pathway, in par-
ticular PTCH1 loss-of-function, as well as gain-of-
function by SHH, SMO and GLI. An important role 
in the genesis of melanoma plays CDKN2A locus on 
9p21, encoding a cyclin-dependent kinase inhibitor 
p16 that acts to inhibit cell cycle progression in the 
G1 phase by binding and inhibiting CDK4/6 kinases. 
Loss of p16 leads to deregulated CDK4/6 action and 
to promotion of cell divisions. Involvement of p16 in 
melanoma development has been demonstrated ei-
ther through loss of heterozygosity (LOH) for DNA 
markers within chromosome 9p21, or by mutational 
screenings of p16. We have been investigating the roles 
of both markers, PTCH and p16, in the pathogenesis 
of both cancers, cutaneous melanoma and basal cell 
carcinoma, and suggested the involvement of SHH/
PTCH/SMO pathway by different mechanisms. Our 
particular interest in the role of SHH/PTCH/SMO 
pathway in various human cancers, which started 
with BCC and has more recently included melanoma, 
is motivated by the potential therapeutic use of small 
molecule antagonists that block the pathway. Anoth-
er promising approach in melanoma research is the 
mitogen-activated protein (MAP) kinase pathway, 
which is affected in 40% to 60% of these carcinomas. 
The pathway is activated by mitogenic signaling from 
the membrane receptors towards the nucleus, which 
begins with the RAS, a small G protein, to pro-
tein kinase BRAF (an enzyme that adds phosphate 
groups to proteins to alter the substrate’s function). 
The BRAF mutation (the V600E mutation) constitu-
tively activates the pathway by increased kinase activ-
ity, leaving the ‘growth’ signal always turned on. It 
has been shown that RAS with oncogenic potential 
to induce melanoma in transgenic mice requires the 
active SHH/PTCH/SMO pathway. Additionally, it 
was found that RAS mediated by MAP and down-
stream AKT signaling regulates the nuclear localiza-
tion and transcriptional activity of GLI1, which is a 
main citoplasmatic oncogene of the SHH/PTCH/
SMO pathway in melanoma cells. All these recent 
findings suggest that an integrated approach to the 
RAS/AKT and SHH/PTCH/SMO pathways has a 
great and possibly synergic potential for future thera-
pies of BCC and particularly of melanoma. 
